Sanofi scraps development of amcenestrant breast cancer treatment

17/8/2022 14:36

        French healthcare company Sanofi said it would end the development programme of amcenestrant, an oestrogen receptor degrader aimed at treating breast cancer.
        
        The move puts more pressure on Sanofi to revive its drug development success rate, after it fell far behind in the race to develop COVID-19 vaccines.
        
        Credit Suisse analyst Jo Walton wrote, "This was a flagship drug in pipeline and important oncology asset," who viewed the update as a "clear negative".
        
        Sanofi said the drug, which was used in combination with an agent known as palbociclib in the study, "did not meet the prespecified boundary for continuation in comparison with the control arm and recommended stopping the trial."